A Congressional hearing on McKinsey & Company’s overlapping consulting work for Purdue Pharma L.P. and the US Food and Drug Administration leaves several questions unanswered, such as whether this will lead to any changes in FDA policies.
The House Committee on Oversight and Reform’s 27 April hearing focused on the advice McKinsey provided to Purdue and its potential conflicts of interest in contracts with the FDA. Rep. Katie Porter, D-Calif
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?